Annual CFF
-$27.63 M
-$225.75 M-113.94%
September 30, 2024
Summary
- As of February 7, 2025, ENTA annual cash flow from financing activities is -$27.63 million, with the most recent change of -$225.75 million (-113.94%) on September 30, 2024.
- During the last 3 years, ENTA annual CFF has fallen by -$30.71 million (-996.95%).
- ENTA annual CFF is now -113.94% below its all-time high of $198.13 million, reached on September 30, 2023.
Performance
ENTA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$7.21 M
-$568.00 K-8.55%
September 30, 2024
Summary
- As of February 7, 2025, ENTA quarterly cash flow from financing activities is -$7.21 million, with the most recent change of -$568.00 thousand (-8.55%) on September 30, 2024.
- Over the past year, ENTA quarterly CFF has dropped by -$7.19 million (-31269.57%).
- ENTA quarterly CFF is now -103.61% below its all-time high of $199.88 million, reached on June 30, 2023.
Performance
ENTA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$27.63 M
-$7.19 M-35.20%
September 30, 2024
Summary
- As of February 7, 2025, ENTA TTM cash flow from financing activities is -$27.63 million, with the most recent change of -$7.19 million (-35.20%) on September 30, 2024.
- Over the past year, ENTA TTM CFF has dropped by -$225.75 million (-113.94%).
- ENTA TTM CFF is now -113.74% below its all-time high of $201.08 million, reached on June 30, 2023.
Performance
ENTA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ENTA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -113.9% | -10000.0% | -113.9% |
| 3 y3 years | -997.0% | -865.1% | -997.0% |
| 5 y5 years | -1173.3% | -865.1% | -997.0% |
ENTA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -113.9% | at low | -103.6% | +1.8% | -113.7% | at low |
| 5 y | 5-year | -113.9% | at low | -103.6% | +1.8% | -113.7% | at low |
| alltime | all time | -113.9% | at low | -103.6% | +1.8% | -113.7% | at low |
Enanta Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | -$27.63 M(-113.9%) | -$7.21 M(+8.5%) | -$27.63 M(+35.2%) |
| Jun 2024 | - | -$6.65 M(+3.6%) | -$20.43 M(-111.0%) |
| Mar 2024 | - | -$6.41 M(-12.7%) | $186.09 M(-2.3%) |
| Dec 2023 | - | -$7.35 M(>+9900.0%) | $190.47 M(-3.9%) |
| Sep 2023 | $198.13 M(+889.0%) | -$23.00 K(-100.0%) | $198.13 M(-1.5%) |
| Jun 2023 | - | $199.88 M(<-9900.0%) | $201.08 M(+3676.8%) |
| Mar 2023 | - | -$2.03 M(-773.4%) | $5.32 M(-50.3%) |
| Dec 2022 | - | $301.00 K(-89.7%) | $10.70 M(-46.6%) |
| Sep 2022 | $20.03 M(+550.4%) | $2.93 M(-28.9%) | $20.03 M(+11.0%) |
| Jun 2022 | - | $4.12 M(+22.9%) | $18.05 M(+23.5%) |
| Mar 2022 | - | $3.35 M(-65.2%) | $14.61 M(+17.7%) |
| Dec 2021 | - | $9.63 M(+921.4%) | $12.41 M(+303.0%) |
| Sep 2021 | $3.08 M(-65.7%) | $943.00 K(+37.5%) | $3.08 M(+30.0%) |
| Jun 2021 | - | $686.00 K(-40.5%) | $2.37 M(-51.7%) |
| Mar 2021 | - | $1.15 M(+285.3%) | $4.91 M(-39.5%) |
| Dec 2020 | - | $299.00 K(+28.3%) | $8.12 M(-9.7%) |
| Sep 2020 | $8.98 M(+249.0%) | $233.00 K(-92.8%) | $8.98 M(-4.8%) |
| Jun 2020 | - | $3.23 M(-26.0%) | $9.44 M(+40.8%) |
| Mar 2020 | - | $4.36 M(+273.8%) | $6.70 M(+157.7%) |
| Dec 2019 | - | $1.17 M(+69.7%) | $2.60 M(+1.0%) |
| Sep 2019 | $2.57 M(-41.6%) | $687.00 K(+40.2%) | $2.57 M(-11.8%) |
| Jun 2019 | - | $490.00 K(+90.7%) | $2.92 M(-45.9%) |
| Mar 2019 | - | $257.00 K(-77.5%) | $5.39 M(+5.1%) |
| Dec 2018 | - | $1.14 M(+10.4%) | $5.13 M(+16.4%) |
| Sep 2018 | $4.41 M | $1.03 M(-65.2%) | $4.41 M(+0.6%) |
| Jun 2018 | - | $2.96 M(<-9900.0%) | $4.38 M(+172.6%) |
| Mar 2018 | - | -$6000.00(-101.4%) | $1.61 M(+14.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | - | $417.00 K(-58.6%) | $1.40 M(+38.0%) |
| Sep 2017 | $1.02 M(-62.4%) | $1.01 M(+430.0%) | $1.02 M(+1332.4%) |
| Jun 2017 | - | $190.00 K(-190.0%) | $71.00 K(-96.2%) |
| Mar 2017 | - | -$211.00 K(-780.6%) | $1.85 M(-28.6%) |
| Dec 2016 | - | $31.00 K(-49.2%) | $2.59 M(-4.3%) |
| Sep 2016 | $2.71 M(+6.5%) | $61.00 K(-96.9%) | $2.71 M(-3.5%) |
| Jun 2016 | - | $1.97 M(+271.3%) | $2.80 M(+192.9%) |
| Mar 2016 | - | $530.00 K(+263.0%) | $957.00 K(+42.4%) |
| Dec 2015 | - | $146.00 K(-8.2%) | $672.00 K(-73.5%) |
| Sep 2015 | $2.54 M(+118.2%) | $159.00 K(+30.3%) | $2.54 M(+4.7%) |
| Jun 2015 | - | $122.00 K(-50.2%) | $2.42 M(-12.7%) |
| Mar 2015 | - | $245.00 K(-87.8%) | $2.78 M(-10.1%) |
| Dec 2014 | - | $2.01 M(+4477.3%) | $3.09 M(+165.4%) |
| Sep 2014 | $1.16 M(-98.0%) | $44.00 K(-90.7%) | $1.16 M(-6.3%) |
| Jun 2014 | - | $474.00 K(-14.9%) | $1.24 M(-283.5%) |
| Mar 2014 | - | $557.00 K(+525.8%) | -$677.00 K(-101.2%) |
| Dec 2013 | - | $89.00 K(-27.0%) | $58.32 M(+2.5%) |
| Sep 2013 | $56.91 M(-6360.8%) | $122.00 K(-108.4%) | $56.91 M(+2.0%) |
| Jun 2013 | - | -$1.45 M(-102.4%) | $55.80 M(-2.5%) |
| Mar 2013 | - | $59.55 M(-4611.7%) | $57.22 M(-2609.6%) |
| Dec 2012 | - | -$1.32 M(+33.2%) | -$2.28 M(+150.8%) |
| Sep 2012 | -$909.00 K(-2773.5%) | -$991.00 K(+3864.0%) | -$909.00 K(-1208.5%) |
| Jun 2012 | - | -$25.00 K(-144.6%) | $82.00 K(-23.4%) |
| Mar 2012 | - | $56.00 K(+9.8%) | $107.00 K(+109.8%) |
| Dec 2011 | - | $51.00 K | $51.00 K |
| Sep 2011 | $34.00 K(+325.0%) | - | - |
| Sep 2010 | $8000.00 | - | - |
FAQ
- What is Enanta Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals annual CFF year-on-year change?
- What is Enanta Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly CFF year-on-year change?
- What is Enanta Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals TTM CFF year-on-year change?
What is Enanta Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ENTA is -$27.63 M
What is the all time high annual CFF for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high annual cash flow from financing activities is $198.13 M
What is Enanta Pharmaceuticals annual CFF year-on-year change?
Over the past year, ENTA annual cash flow from financing activities has changed by -$225.75 M (-113.94%)
What is Enanta Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ENTA is -$7.21 M
What is the all time high quarterly CFF for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high quarterly cash flow from financing activities is $199.88 M
What is Enanta Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, ENTA quarterly cash flow from financing activities has changed by -$7.19 M (-31269.57%)
What is Enanta Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ENTA is -$27.63 M
What is the all time high TTM CFF for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high TTM cash flow from financing activities is $201.08 M
What is Enanta Pharmaceuticals TTM CFF year-on-year change?
Over the past year, ENTA TTM cash flow from financing activities has changed by -$225.75 M (-113.94%)